Tech Company Financing Transactions
Thrasos Therapeutics Funding Round
On 4/1/2015, Thrasos Therapeutics received $21 million in Series D funding from BDC Venture Capital and SR One Capital Management.
Transaction Overview
Company Name
Announced On
4/1/2015
Transaction Type
Venture Equity
Amount
$21,000,000
Round
Series D
Investors
BDC Venture Capital (Lead Investor) (Ela Borenstein)
SR One Capital Management (Jens Eckstein)
Proceeds Purpose
These funds will also allow us to significantly extend the development of our core technology into Chronic Kidney Disease (CKD).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
7171 Frederick Banting 1228
Montreal QC, H4S 1Z9
Canada
Montreal QC, H4S 1Z9
Canada
Phone
Website
Email Address
Overview
Thrasos is a private, clinical-stage biotherapeutics company focused on bringing new solutions to kidney disease patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joseph Zakrzewski
Chief Financial Officer
Donald Notman
Chief Scientific Officer
Jerome Rossert
Vice President
Philippe Bey
Browse more venture capital transactions:
Prev: 4/1/2015: KeepTrax venture capital transaction
Next: 4/1/2015: TaaSera venture capital transaction
Share this article
About Database of VC Transactions
We do our best to document funding rounds that are announced publicly. VC investment data records reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs